|Bid||3.4400 x 800|
|Ask||4.6800 x 800|
|Day's Range||3.4600 - 3.8000|
|52 Week Range||3.2200 - 11.2270|
|Beta (3Y Monthly)||1.04|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
The Burlingame, California-based company said it had a loss of 40 cents per share. In the final minutes of trading on Thursday, the company's shares hit $4.11. A year ago, they were trading at $9.70. _____ ...
If you love investing in stocks you're bound to buy some losers. But the last three years have been particularly tough on longer term Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) shareholders. Regrettably, they have had to cope...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention Read More...
Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is also making good progress. The company is also developing gene therapies.
The Burlingame, California-based company said it had a loss of 36 cents per share. Corvus shares have dropped 21 percent since the beginning of the year. The stock has declined 41 percent in the last 12 ...